Researcher
Pieter Van Der Veken
- Research Expertise:Medicinal chemistry & drug discovery, pharmaceutical chemistry, organic chemistry & organic synthesis
- Keywords:ORGANIC CHEMISTRY, MEDICINAL CHEMISTRY, DRUG DISCOVERY, Pharmacy and pharmacology
- Disciplines:(Bio)molecular modelling and design, Characterisation of biologically active (macro)molecules, Medicinal and biomolecular chemistry not elsewhere classified, Bio-organic chemistry, Organic chemical synthesis, Medicinal chemistry
- Research techniques:Drug design, organic synthesis, characterization of molecules via NMR spectroscopy, mass spectrometry and other analytical techniques
- Users of research expertise:Pharmaceutical and biotech-industry
Affiliations
- Medicinal Chemistry (UAMC) (Research group)
Member
From1 Oct 2003 → Today
Projects
31 - 40 of 74
- Impact of extracellular matrix organization in the tumor environment on efficacy of immunotherapy in DNA mismatch repair deficient tumors.From1 Sep 2019 → 31 Aug 2023Funding: Nonprofit institution or equivalents
- Personalized immune therapy: FAP as a marker for resistance to immune checkpoint therapy in urothelial carcinomas.From1 Sep 2019 → 31 Dec 2022Funding: VLAIO - research project companies
- Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors (RespiriTB).From1 May 2019 → TodayFunding: H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and wellbeing
- Progress novel assets (one FIH start) for nontubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs (RespiriNTM).From1 May 2019 → TodayFunding: Fund Recuperation Fiscal Exemption, H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and wellbeing
- Validation of the oxadiazolone isostere as a carboxylate replacement in caspase inhibitors: approaches involving Strecker-based synthetic methodology development and on-target strategies.From1 Oct 2018 → 30 Sep 2021Funding: FWO fellowships
- Development of novel cell death PET imaging probes for early treatment response assessment.From1 Oct 2018 → 30 Sep 2022Funding: BOF - Doctoral projects
- The Biomolecular Interaction Platform (BIP) at UAntwerp.From1 May 2018 → 30 Apr 2021Funding: FWO Medium Size Research Infrastructure
- Synthesis of inhibitors and inhibitor-derived imaging probes for prolyl oligopeptidase (PREP) and dipeptidyl-peptidase (DPP9) with potential application in neurodegenerative disease.From1 Jan 2018 → 31 Mar 2022Funding: FWO Strategic Basic Research Grant
- Preclinical characterization and biopharmaceutical optimization of the autophagy inhibitor UAMC-2526 for oncotherapy.From1 Jan 2018 → 31 Dec 2020Funding: IOF - Industrial Research Fund
- Inhibitors of prolyl oligopeptidase (PREP) as novel candidates for tackling synucleinopathies: insight in structural, thermodynamic and kinetic parameters that determine inhibitor potential to block PREP-promoted alpha-Synuclein aggregationFrom1 Oct 2017 → 30 Sep 2020Funding: FWO fellowships
Publications
1 - 10 of 128
- Design and synthesis of selective DPP9 inhibitors(2024)
Authors: Siham Benramdane, Pieter Van Der Veken, Hans De Winter
Number of pages: 232 - Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics(2023)
Authors: Marcel Martin, Sanjana Ballal, Madhav Prasad Yadav, Chandrasekhar Bal, Yentl Van Rymenant, Joni De Loose, Emile Verhulst, Ingrid De Meester, Pieter Van Der Veken, Frank Roesch
Pages: 1 - 25 - From PERK to RIPK1(2023)
Authors: Camilla Scarpellini, Sophie Valembois, Kenneth Goossens, Mike Vadi, Caroline Lanthier, Greta Klejborowska, Pieter Van Der Veken, Hans De Winter, Mathieu J.M. Bertrand, Koen Augustyns
Pages: 1 - 15 - Next generation fibroblast activation protein (FAP) targeting PET tracers(2023)
Authors: Christian B.M. Poulie, Vladimir Shalgunov, Filipe Elvas, Yentl Van Rymenant, Euy-Sung Moon, Umberto Maria Battisti, Joni De Loose, Ingrid De Meester, Frank Rösch, Pieter Van Der Veken, et al.
Pages: 1 - 10 - Characterization of structurally diverse ¹⁸F-labeled d-TCO derivatives as a PET probe for bioorthogonal pretargeted imaging(2023)
Authors: Karuna Adhikari, Christel Vangestel, Pieter Van Der Veken, Sigrid Stroobants, Filipe Elvas, Koen Augustyns
Pages: 38252 - 38262 - Chemically diverse activity-based probes with unexpected inhibitory mechanisms targeting trypsin-like serine proteases(2023)
Authors: Alba Ramos Llorca, Lisse Decraecker, Valerie Cacheux, Irena Zeiburlina, Michelle De bruyn, Louise Battut, Carlos Moreno Cinos, Davide Ceradini, Eric Espinosa, Gilles Dietrich, et al.
Pages: 1 - 17 - Highly selective inhibitors of dipeptidyl peptidase 9 (DPP9) derived from the clinically used DPP4-inhibitor vildagliptin(2023)
Authors: Siham Benramdane, Joni De Loose, Nicolò Filippi, Margarida Florindo Espadinha, Olivier Beyens, Yentl Van Rymenant, Laura Dirkx, Murat Bozdag, Koen Augustyns, Guy Caljon, et al.
Pages: 12717 - 12738 - Design, synthesis and evaluation of novel activity-based probes and inhibitors for trypsin-like serine proteases(2023)
Authors: Alba Ramos Llorca, Koen Augustyns, Pieter Van Der Veken
Number of pages: 289 - Vildagliptin‐derived dipeptidyl peptidase 9 (DPP9) inhibitors(2022)
Authors: Siham Benramdane, Joni De Loose, Olivier Beyens, Yentl Van Rymenant, Gwendolyn Vliegen, Koen Augustyns, Hans De Winter, Ingrid De Meester, Pieter Van Der Veken
Pages: 1 - 16 - Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients(2022)
Authors: An Bracke, Emilie De Hert, Michelle De bruyn, Karen Claesen, Gwendolyn Vliegen, Alexandra Vujkovic, Lida van Petersen, Fien De Winter, An Hotterbeekx, Isabel Brosius, et al.
Pages: 4 - 11
Patents
1 - 10 of 10
- 3-(Benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. Stroke (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- Halogenated benzotropolones as ATG4B inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- KLK4 inhibitors (Inventor)